The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk

209 postmenopausal osteoporotic women who were randomized in the TOWER trial in 2012 were analyzed to evaluate bone structural and strength changes at the hip after treatment with Teriparatide injection or placebo over 72 weeks. Patients were evaluated using hip structural analysis (HSA) based on dual-energy X-ray absorptiometry. The evidence presented in this trial demonstrated that Teriparatide treatment produced significantly higher bone mineral density (BMD), average cortical thickness, bone cross-sectional area, section modulus, and lower buckling ratio at both the narrowest point of the neck (NN) and the intertrochanteric region (IT) compared to the placebo treatment.